BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 24725760)

  • 1. Clinical role of pathological downgrading after radical prostatectomy in patients with biopsy confirmed Gleason score 3 + 4 prostate cancer.
    Gondo T; Poon BY; Matsumoto K; Bernstein M; Sjoberg DD; Eastham JA
    BJU Int; 2015 Jan; 115(1):81-6. PubMed ID: 24725760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PI-RADS version 2 for prediction of pathological downgrading after radical prostatectomy: a preliminary study in patients with biopsy-proven Gleason Score 7 (3+4) prostate cancer.
    Woo S; Kim SY; Lee J; Kim SH; Cho JY
    Eur Radiol; 2016 Oct; 26(10):3580-7. PubMed ID: 26847042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preoperative characteristics of high-Gleason disease predictive of favourable pathological and clinical outcomes at radical prostatectomy.
    Pierorazio PM; Ross AE; Lin BM; Epstein JI; Han M; Walsh PC; Partin AW; Pavlovich CP; Schaeffer EM
    BJU Int; 2012 Oct; 110(8):1122-8. PubMed ID: 22373045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Should all prostate needle biopsy Gleason score 4 + 4 = 8 prostate cancers be high risk? Implications for shared decision-making and patient counselling.
    Ginsburg K; Cole AI; Silverman ME; Livingstone J; Smith DW; Heilbrun LK; Shi D; Mehra R; Sakr WA; Morgan TM; Cher ML
    Urol Oncol; 2020 Mar; 38(3):78.e1-78.e6. PubMed ID: 31791703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does cumulative prostate cancer length (CCL) in prostate biopsies improve prediction of clinically insignificant cancer at radical prostatectomy in patients eligible for active surveillance?
    Chen DJ; Falzarano SM; McKenney JK; Przybycin CG; Reynolds JP; Roma A; Jones JS; Stephenson A; Klein E; Magi-Galluzzi C
    BJU Int; 2015 Aug; 116(2):220-9. PubMed ID: 25060664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse Disease Features in Gleason Score 3 + 4 "Favorable Intermediate-Risk" Prostate Cancer: Implications for Active Surveillance.
    Morlacco A; Cheville JC; Rangel LJ; Gearman DJ; Karnes RJ
    Eur Urol; 2017 Sep; 72(3):442-447. PubMed ID: 27574819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades.
    Epstein JI; Feng Z; Trock BJ; Pierorazio PM
    Eur Urol; 2012 May; 61(5):1019-24. PubMed ID: 22336380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nomogram Predicting Downgrading in National Comprehensive Cancer Network High-risk Prostate Cancer Patients Treated with Radical Prostatectomy.
    Wenzel M; Würnschimmel C; Chierigo F; Flammia RS; Tian Z; Shariat SF; Gallucci M; Terrone C; Saad F; Tilki D; Graefen M; Becker A; Kluth LA; Mandel P; Chun FKH; Karakiewicz PI
    Eur Urol Focus; 2022 Sep; 8(5):1133-1140. PubMed ID: 34334344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Limitations in Predicting Organ Confined Prostate Cancer in Patients with Gleason Pattern 4 on Biopsy: Implications for Active Surveillance.
    Perlis N; Sayyid R; Evans A; Van Der Kwast T; Toi A; Finelli A; Kulkarni G; Hamilton R; Zlotta AR; Trachtenberg J; Ghai S; Fleshner NE
    J Urol; 2017 Jan; 197(1):75-83. PubMed ID: 27457260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unilateral positive biopsies in low risk prostate cancer patients diagnosed with extended transrectal ultrasound-guided biopsy schemes do not predict unilateral prostate cancer at radical prostatectomy.
    Gallina A; Maccagnano C; Suardi N; Capitanio U; Abdollah F; Raber M; Salonia A; Scattoni V; Rigatti P; Montorsi F; Briganti A
    BJU Int; 2012 Jul; 110(2 Pt 2):E64-8. PubMed ID: 22093108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Downgrading of grade group 2 intermediate-risk prostate cancer from biopsy to radical prostatectomy: Comparison of outcomes and predictors to identify potential candidates for active surveillance.
    Su ZT; Patel HD; Epstein JI; Pavlovich CP; Allaf ME
    Cancer; 2020 Apr; 126(8):1632-1639. PubMed ID: 32031685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concordance between Gleason score of prostate biopsies and radical prostatectomy specimens and its predictive factors.
    Ariafar A; Rezaeian A; Zare A; Zeighami S; Hosseini SH; Nikbakht HA; Narouie B
    Urologia; 2023 May; 90(2):236-243. PubMed ID: 35972023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate cancer upgrading or downgrading of biopsy Gleason scores at radical prostatectomy: prediction of "regression to the mean" using routine clinical features with correlating biochemical relapse rates.
    Altok M; Troncoso P; Achim MF; Matin SF; Gonzalez GN; Davis JW
    Asian J Androl; 2019; 21(6):598-604. PubMed ID: 31115364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Poorly differentiated prostate cancer treated with radical prostatectomy: long-term outcome and incidence of pathological downgrading.
    Donohue JF; Bianco FJ; Kuroiwa K; Vickers AJ; Wheeler TM; Scardino PT; Reuter VA; Eastham JA
    J Urol; 2006 Sep; 176(3):991-5. PubMed ID: 16890678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Impact of Downgrading from Biopsy Gleason 7 to Prostatectomy Gleason 6 on Biochemical Recurrence and Prostate Cancer Specific Mortality.
    Ham WS; Chalfin HJ; Feng Z; Trock BJ; Epstein JI; Cheung C; Humphreys E; Partin AW; Han M
    J Urol; 2017 Apr; 197(4):1060-1067. PubMed ID: 27847296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Downgrading of biopsy based Gleason score in prostatectomy specimens.
    Treurniet KM; Trudel D; Sykes J; Evans AJ; Finelli A; Van der Kwast TH
    J Clin Pathol; 2014 Apr; 67(4):313-8. PubMed ID: 24403214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of predictors of unfavorable pathological features in men eligible for active surveillance using radical prostatectomy specimens: a multi-institutional study.
    Mizuno K; Inoue T; Kinoshita H; Yano T; Kawanishi H; Kanda H; Terada N; Kobayashi T; Kamba T; Mikami Y; Shiraishi T; Uemura Y; Imai Y; Honjo G; Shirase T; Okumura K; Kawakita M; Ogura K; Sugimura Y; Matsuda T; Ogawa O
    Jpn J Clin Oncol; 2016 Dec; 46(12):1156-1161. PubMed ID: 27744325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy.
    Sebo TJ; Bock BJ; Cheville JC; Lohse C; Wollan P; Zincke H
    J Urol; 2000 Jan; 163(1):174-8. PubMed ID: 10604340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adenocarcinoma of the prostate with Gleason score 9-10 on core biopsy: correlation with findings at radical prostatectomy and prognosis.
    Ellis CL; Partin AW; Han M; Epstein JI
    J Urol; 2013 Dec; 190(6):2068-73. PubMed ID: 23727307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate-specific antigen vs prostate-specific antigen density as a predictor of upgrading in men diagnosed with Gleason 6 prostate cancer by contemporary multicore prostate biopsy.
    Oh JJ; Hong SK; Lee JK; Lee BK; Lee S; Kwon OS; Byun SS; Lee SE
    BJU Int; 2012 Dec; 110(11 Pt B):E494-9. PubMed ID: 22540236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.